Postinflammatory hyperpigmentation
Postinflammatory hyperpigmentation ni hali ya ngozi inayoonyeshwa na kuongezeka kwa rangi kwenye ngozi kufuatia kuvimba kwa ngozi. Postinflammatory hyperpigmentation inaweza kusababishwa na kupigwa na jua kwa muda mrefu, kuvimba, au majeraha mengine ya ngozi, ikiwa ni pamoja na yale yanayohusiana na chunusi. Watu walio na ngozi nyeusi kwa kawaida huwa na uwezekano mkubwa wa kupata rangi nyekundu na kupigwa na jua kupita kiasi.
☆ Katika matokeo ya 2022 ya Stiftung Warentest kutoka Ujerumani, kuridhika kwa watumiaji na ModelDerm kulikuwa chini kidogo kuliko na mashauriano ya matibabu ya simu yanayolipishwa.
References
Postinflammatory hyperpigmentation (PIH) ni tatizo la ngozi la mara kwa mara ambalo hutokea baada ya ngozi kuvimba au kuumia. Inaelekea kudumu kwa muda mrefu na ni mbaya zaidi kwa watu wenye ngozi nyeusi (Fitzpatrick skin types III–VI) . Ingawa mara nyingi hupata nafuu yenyewe, hii inaweza kuchukua muda, hivyo matibabu mara nyingi inahitajika kwa muda mrefu. Kuchanganya matibabu tofauti hufanya kazi vizuri zaidi.
Postinflammatory hyperpigmentation (PIH) is a common acquired cutaneous disorder occurring after skin inflammation or injury. It is chronic and is more common and severe in darker-skinned individuals (Fitzpatrick skin types III–VI). While the condition typically improves spontaneously, this process can take months to years, necessitating prolonged treatment. Combination therapy is the most effective.
Postinflammatory hyperpigmentation (PIH) is a common acquired cutaneous disorder occurring after skin inflammation or injury. It is chronic and is more common and severe in darker-skinned individuals (Fitzpatrick skin types III–VI). While the condition typically improves spontaneously, this process can take months to years, necessitating prolonged treatment. Combination therapy is the most effective.
Postinflammatory hyperpigmentation ni matokeo ya kawaida ya kuvimba kwa ngozi. Inaelekea kuathiri watu wenye ngozi nyeusi kwa ukali zaidi na mara kwa mara. Uchunguzi unaonyesha kuwa masuala kama postinflammatory hyperpigmentation ni miongoni mwa sababu kuu zinazowafanya watu walio na ngozi nyeusi kutafuta huduma ya ngozi. Matibabu ya mapema ni muhimu katika kutatua postinflammatory hyperpigmentation na kwa kawaida huanza na kudhibiti hali ya awali ya uvimbe. Mstari wa kwanza wa matibabu kwa kawaida huhusisha matumizi ya vijenzi ambavyo hung'arisha ngozi pamoja na mafuta ya kujikinga na jua. Mawakala hawa, kama hydroquinone, azelaic acid, kojic acid, arbutin, licorice extracts , wanaweza kupunguza upakaji rangi kupita kiasi. Zaidi ya hayo, retinoids, mequinol, ascorbic acid, niacinamide, N-acetyl glucosamine, soy pia hutumika kama mawakala wa kuondoa rangi, na matibabu mapya yakiibuka. Ingawa matibabu ya kimaadili kwa kawaida huwa na ufanisi kwa kiwango cha juu cha rangi ya ngozi, taratibu (laser, chemical peel) zinaweza kuhitajika kwa visa vya ukaidi. Ni muhimu kutumia tahadhari na matibabu haya ili kuepuka kuwashwa na kuongezeka kwa postinflammatory hyperpigmentation.
Postinflammatory hyperpigmentation is a common sequelae of inflammatory dermatoses that tends to affect darker skinned patients with greater frequency and severity. Epidemiological studies show that dyschromias, including postinflammatory hyperpigmentation, are among the most common reasons darker racial/ethnic groups seek the care of a dermatologist. The treatment of postinflammatory hyperpigmentation should be started early to help hasten its resolution and begins with management of the initial inflammatory condition. First-line therapy typically consists of topical depigmenting agents in addition to photoprotection including a sunscreen. Topical tyrosinase inhibitors, such as hydroquinone, azelaic acid, kojic acid, arbutin, and certain licorice extracts, can effectively lighten areas of hypermelanosis. Other depigmenting agents include retinoids, mequinol, ascorbic acid, niacinamide, N-acetyl glucosamine, and soy with a number of emerging therapies on the horizon. Topical therapy is typically effective for epidermal postinflammatory hyperpigmentation; however, certain procedures, such as chemical peeling and laser therapy, may help treat recalcitrant hyperpigmentation. It is also important to use caution with all of the above treatments to prevent irritation and worsening of postinflammatory hyperpigmentation.
Postinflammatory hyperpigmentation is a common sequelae of inflammatory dermatoses that tends to affect darker skinned patients with greater frequency and severity. Epidemiological studies show that dyschromias, including postinflammatory hyperpigmentation, are among the most common reasons darker racial/ethnic groups seek the care of a dermatologist. The treatment of postinflammatory hyperpigmentation should be started early to help hasten its resolution and begins with management of the initial inflammatory condition. First-line therapy typically consists of topical depigmenting agents in addition to photoprotection including a sunscreen. Topical tyrosinase inhibitors, such as hydroquinone, azelaic acid, kojic acid, arbutin, and certain licorice extracts, can effectively lighten areas of hypermelanosis. Other depigmenting agents include retinoids, mequinol, ascorbic acid, niacinamide, N-acetyl glucosamine, and soy with a number of emerging therapies on the horizon. Topical therapy is typically effective for epidermal postinflammatory hyperpigmentation; however, certain procedures, such as chemical peeling and laser therapy, may help treat recalcitrant hyperpigmentation. It is also important to use caution with all of the above treatments to prevent irritation and worsening of postinflammatory hyperpigmentation.
